Another mechanism that exploits the tumor-killing ability of neutrophils is using TGF-β-blocking antibodies either as monotherapy or as combination therapy with [191] fresolimumab, which has been shown to be used in patients with melanoma [192], renal cell carcinoma [193], and metastatic breast cancer [194]. The gene discussed is TGFB1; the disease is melanoma.